Drugs / Montanide(R) ISA-51 VG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05898828 | Aug 2024 | esophageal cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Montanide(R) ISA-51 VG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898828 ↗ |
| Route | Subcutaneous | “Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections” NCT05898828 ↗ |